Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
Clinical Gastroenterology and Hepatology · 2023-08 · 21 (9) · 2421-2423.e2
DOI: 10.1016/j.cgh.2022.07.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-08. Verfasst von Yeonjung Ha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Esophageal and Gastric Varices, Liver Neoplasms, Varicose Veins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science, ICT and Future Planning, National Research Foundation of Korea.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a major contributor to the global health burden, affecting more than 800,000 new patients annually and comprising the 4th leading cause of cancer-related mortality.1-3 The combination of atezolizumab and bevacizumab (atezo/bev) was approved as a first-line systemic therapy for advanced HCC;4,5 however, adverse events need to be validated in a real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea.
- Department of Radiology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea. Electronic address: chan@cha.ac.kr.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea. Electronic address: minidoctor@cha.ac.kr.
Förderung
- Ministry of Science, ICT and Future Planning
- National Research Foundation of Korea
Zitieren
APA
Ha, Y., Kim, J. H., Cheon, J., Jeon, G. S., Kim, C., & Chon, H. J. (2023). Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab. Clinical Gastroenterology and Hepatology, 21(9), 2421-2423.e2. https://doi.org/10.1016/j.cgh.2022.07.035
Vancouver
Ha Y, Kim JH, Cheon J, Jeon GS, Kim C, Chon HJ. Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab. Clinical Gastroenterology and Hepatology. 2023;21(9):2421-2423.e2. doi:10.1016/j.cgh.2022.07.035
BibTeX
@article{Ha2023,
author = {Ha, Yeonjung and Kim, Jee Hyun and Cheon, Jaekyung and Jeon, Gyeong Sik and Kim, Chan and Chon, Hong Jae},
title = {Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
volume = {21},
number = {9},
pages = {2421--2423.e2},
doi = {10.1016/j.cgh.2022.07.035}
}
EUVIMED